VERA NASDAQ
Vera Therapeutics, Inc.
1W: +0.2%
1M: +16.9%
3M: +4.2%
YTD: -27.9%
1Y: +43.9%
3Y: +87.2%
5Y: +80.3%
$35.05
+1.45 (+4.32%)
Weekly Expected Move ±8.3%
$29
$32
$35
$38
$41
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.5B
52W Range22.72-56.05
Volume3,796,712
Avg Volume1,825,182
Beta0.95
Dividend—
Analyst Ratings
Company Info
CEOMarshall Fordyce
Employees361
SectorHealthcare
IndustryBiotechnology
IPO Date2021-05-14
Websiteveratx.com
2000 Sierra Point Parkway
Brisbane, CA 94005
US
Brisbane, CA 94005
US
650 770 0077
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Latest News
Most shorted stocks on Wall Street
E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of “Moderate Buy” by Brokerages
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Is Vera Therapeutics, Inc. (VERA) A Good Stock To Buy Now?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fordyce Marshall | S-Sale | 18,500 | $35.12 | 2026-09-02 |
| Boman Nancy Lee | A-Award | 44,987 | — | 2026-08-03 |
| Boman Nancy Lee | A-Award | 63,011 | $32.23 | 2026-08-03 |
| Boman Nancy Lee | 0 | — | 2026-08-03 | |
| Fordyce Marshall | S-Sale | 1,000 | $40.78 | 2026-07-07 |